Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine + Peginterferon alfa-2a in Advanced HCC
NCT02576964Phase 2Completed
- Sponsor
- Roche
- Start
- Jan 2005
- Primary completion
- Nov 2008
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of capecitabine and peginterferon alfa-2a in hepatocellular carcinoma (HCC), sponsored by Roche. Primary endpoint: Objective Response Rate at 46 months. Started Jan 2005; status: completed.
02
Drugs
capecitabinepeginterferon alfa-2a
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02576964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02576964.